GEMIFLOXACIN MESYLATE (gemifloxacin mesylate) by LG Chem Life Sciences is clinical pharmacology pharmacokinetics the pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. Approved for infections caused by susceptible strains of the designated microorganisms in the conditions listed below. First approved in 2015.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. There was minimal accumulation of gemifloxacin following multiple oral doses up to 640 mg a day for 7 days (mean accumulation <20%). Following repeat oral…
Worked on GEMIFLOXACIN MESYLATE at LG Chem Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.